ArticleEndocrine2026
Integrating the Ki67 proliferation index into risk-adapted management of medullary thyroid carcinoma: evidence from the first large retrospective chinese cohort.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo evaluate the clinical implications of the Ki67 proliferation index in medullary thyroid carcinoma (MTC), focusing on its association with lateral lymph node metastasis (LLNM) and disease-free survival (DFS) to refine risk-adapted management.
methodsA retrospective cohort of 148 consecutive patients who underwent initial thyroidectomy for MTC (2008-2024) was analyzed. Patients were stratified by Ki67 index according to IMTCGS criteria (< 5% vs. ≥ 5%). Comprehensive clinicopathological and lymph node data were collected. The primary endpoints were associations between Ki67 index and nodal metastatic burden, as well as postoperative DFS. Multivariate logistic and Cox regression models were used to identify independent predictors of LLNM and DFS.
resultsAmong the 148 patients, 37 exhibited high Ki67 expression (≥ 5%). Elevated Ki67 was significantly associated with aggressive clinicopathological features, including higher preoperative calcitonin levels, larger tumors, advanced T-stage, and higher rates of LLNM. Furthermore, Spearman analysis revealed a positive correlation between the Ki67 index and lymph node metastatic burden. Kaplan-Meier survival analysis demonstrated that high Ki67 (≥ 5%) predicted significantly worse DFS (HR = 3.389, P = 0.003) and distant metastasis-free survival ( HR = 4.958, P = 0.018). Further stratification revealed that patients with Ki67 ≥ 20% exhibited the worst DFS (HR = 5.589, 95% CI: 1.135-27.522) compared to the < 5% baseline. Multivariate analysis confirmed Ki67 ≥ 5% as an independent predictor for worse DFS (HR = 2.60, P = 0.029), and this association remained significant in patients with regional disease (P = 0.021).
conclusionsThe Ki67 index positively correlates with lymph node metastatic burden and provides critical prognostic value for MTC. An index ≥ 5% independently predicts inferior DFS, particularly in regional disease, while an index ≥ 20% identifies patients requiring intensive surveillance. Integrating Ki67 evaluation facilitates optimal risk stratification, though adopting the complete IMTCGS remains recommended.
Indexed as
Identifiers
42228227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.